- * Have a confirmed diagnosis of CF: one or more clinical findings consistent with CF and at least one of the following:
- 1. Sweat chloride ≥ 60 mEq/L by quantitative pilocarpine iontophoresis test OR
- 2. A genotype with two identifiable mutations consistent with CF (∆F508 homozygous or two alleles known to cause a class I, II, or III mutation)
- * Have an FEV1 ≥30% of predicted normal as defined by age, gender, and height
Cystic Fibrosis
Safety and Tolerability Study of Liquid Alpha1 Proteinase Inhibitor (API) in Subjects With Cystic Fibrosis
NCT01347190 | PHASE 1 | INTERVENTIONAL
Study to assess safety and tolerability of a single dose of study-drug administered to Cystic Fibrosis (CF) patients.
Trial Information
If interested, contact clinicaltrials@cslbehring.com for more information
CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy
Site
Sofia,Bulgaria
Site
Varna,Bulgaria
Site
Debrecen,Hungary
Site
Bialystok,Poland
Site
Gdansk,Poland
Site
Poznan,Poland
Site
Rabka Zdroj,Poland
Site
Warszawa,Poland
Site
Papworth Hospital,United Kingdom
Site
Penarth,United Kingdom
Site
Southampton,United Kingdom
Study Eligibility Criteria
Additional Studies
Additional studies can be found at ClinicalTrials.gov